Yahoo Poland Wyszukiwanie w Internecie

Zaloguj się

Search results

  1. www.idsociety.org › practice-guideline › covid-19-guideline-treatment-and-managementIDSA Guidelines on the Treatment and Management of Patients with...

    IDSA has developed living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19 infection.

    • Paxlovid

      This website uses cookies. We use cookies to ensure that we...

    • Antigen Testing

      December 20, 2022. Version 2.0.0 has been released and...

    • Serology

      Serologic tests for severe acute respiratory syndrome...

    • Training and Resources

      Guideline Panelists; Clinical Practice Guidelines...

  2. www.ncbi.nlm.nih.gov › pmc › articlesRole for digoxin in patients hospitalized with COVID‐19 and...

    1 lut 2021 · We agree with Siniorakis et al. that given that a significant proportion of patients in our study were on vasopressor support, digoxin may be particularly useful in patients with COVID‐19 and atrial arrhythmias whose hypotension may preclude the use of beta blockers and calcium channel blockers. However, in the absence of prospective ...

  3. www.nature.com › articles › s41598/020/72879-7Antiviral activity of digoxin and ouabain against SARS-CoV-2 ......

    1 paź 2020 · Collectively, these results suggest that DIG and OUA may be an alternative treatment for COVID-19, with potential additional therapeutic effects for patients with cardiovascular disease.

  4. pubmed.ncbi.nlm.nih.gov › 33522631Role for digoxin in patients hospitalized with COVID-19 and ... -...

    Role for digoxin in patients hospitalized with COVID-19 and atrial arrhythmias. J Cardiovasc Electrophysiol. 2021 Feb 1. doi: 10.1111/jce.14901. Online ahead of print. Authors. Bradley Peltzer 1 , Bruce B Lerman 1 , Parag Goyal 1 , Jim W Cheung 1. Affiliation.

  5. ejhp.bmj.com › content › 29Benefit versus toxicity risk of digoxin in patients with COVID-19

    In general, the incidence of toxicity is reported to be about 1% in patients with CHF treated with digoxin. 1 Increased intracellular calcium due to inhibition of Na–K transporter is the primary pathway of digoxin toxicity. 2 Factors such as renal function, …

  6. www.ncbi.nlm.nih.gov › pmc › articlesBenefit versus toxicity risk of digoxin in patients with COVID-19

    2 cze 2021 · The beneficial effect of digoxin in patients with COVID-19 and atrial arrhythmias has been reported. Several studies have also reported on the antiviral and anti-inflammatory properties of cardiac glycosides via inhibition of the entrance of coronavirus into the cells and suppression of a cytokine storm. 3

  7. www.ncbi.nlm.nih.gov › pmc › articlesAntiviral activity of digoxin and ouabain against SARS-CoV-2...

    1 paź 2020 · Digoxin (DIG) and ouabain (OUA) are FDA drugs for heart diseases that have antiviral activity against several coronaviruses. Thus, we aimed to assess antiviral activity of DIG and OUA against SARS-CoV-2 infection. The half-maximal inhibitory concentrations (IC 50) of DIG and OUA were determined at a nanomolar concentration.